Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

Dearnaley, David P.; Sydes, Matthew R.; Graham, John D.; Aird, Edwin; Bottomley, David; Cowan, Richard A; Huddart, Robert; Jose, C.C.; Matthews, John; Millar, Jeremy; Moore, Andrea; Morgan, Rachel C.; Russell, John M.; Scrase, Christopher; Stephens, Richard; Syndikus, Isabel; Parmar, Mahesh

doi:10.1016/s1470-2045(07)70143-2

Cited by 847 publications

(498 citation statements)

References 45 publications

Supporting

Mentioning

466

Contrasting

Unclassified

Order By: Relevance

“…This study has therefore shown benefits from dose escalation for men with higher-risk tumours known to have a poorer outcome with traditional doses of radiotherapy. This observation has been supported by findings from the MRC RT01 study [19]. In this 3DCRT trial, 843 men were randomized to a standard dose of 64 Gy compared with an escalated dose of 74 Gy.…”

Section: Radiotherapymentioning

confidence: 65%

Management of locally advanced prostate cancer

Payne¹

2008

Asian J Androl

View full text Add to dashboard Cite

The management of all stages of prostate cancer is an increasingly complex process and involves a variety of available treatments and many disciplines. Despite prostate-specific antigen (PSA) testing, the presentation of prostate cancer at a locally advanced stage is common in the UK, accounting for one-third of all new cases. There is no universally accepted definition of locally advanced prostate cancer; the term is loosely used to encompass a spectrum of disease profiles that show high-risk features. Men with high-risk prostate cancer generally have a significant risk of disease progression and cancer-related death if left untreated. High-risk patients, including those with locally advanced disease, present two specific challenges. There is a need for local control as well as a need to treat any microscopic metastases likely to be present but undetectable until disease progression. The optimal treatment approach will therefore often necessitate multiple modalities. The exact combinations, timing and intensity of treatment continue to be strongly debated. Management decisions should be made after all treatments have been discussed by a multidisciplinary team (including urologists, oncologists, radiologists, pathologists and nurse specialists) and after the balance of benefits and side effects of each therapy modality has been considered by the patient with regard to his own individual circumstances. This article reviews the current therapy options.

show abstract

Section: Radiotherapymentioning

confidence: 65%

Management of locally advanced prostate cancer

Payne¹

2008

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…NO-sulindac was found to have a SER of 1. [26]. Crucially, at 2Gy, NO-sulindac resulted in a significant radiosensitising effect over control treated cells under both normoxia (up to 2.2 fold reduction in cell survival) and hypoxia (1.9 fold reduction in survival).…”

Section: Discussionmentioning

confidence: 89%

DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions

Stewart

Nanda

Katz

et al. 2011

Biochemical Pharmacology

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. *ManuscriptPage 2 of 32 A c c e p t e d M a n u s c r i p t 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64

show abstract

“…In the past, the prescribed radiation dose ranged from 64 to 70 Gy delivered in fractions of 1.8-2 Gy, although data from clinical trials 1,2 showed that such doses were insufficient to achieve better disease control. However, it was not possible to increase the maximum doses with conventional EBRT due to toxicity risk (primarily to the bladder and rectum).…”

Section: Introductionmentioning

confidence: 99%

Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre

Boladeras

Martinez

Ferrer

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Results: Median follow-up was 109.6 months (range, 68.3-193.4 and 71.4% (high) (p = 0.0666). Toxicity included rectitis: grade 1 (G1) (277 pts; 32.6%), G2 (108; 12.7%), and G3 (20; 2.6%) and urethritis: G1 (294; 34.6%); G2 (223; 26.2%), and G3 (11; 1.3%). By dose rate (<76 Gy vs. ≥76 Gy), 5 and 10-year BRFS rates were 83.1% and 68.3% vs. 88.4% and 74.8% (p = 0.038). Conclusions:Our results are comparable to other published series in terms of disease control and toxicity. These findings confirm the need for dose escalation to achieve better biochemical control and the benefits of ADT in high-risk PCa patients.

show abstract

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

Cited by 847 publications

References 45 publications

Management of locally advanced prostate cancer

Management of locally advanced prostate cancer

DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions

Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre

Contact Info

Product

Resources

About